109558-73-8

Upstream product

• 92-91-1 biphenyl-4-acetaldehyde 
• 904583-85-3 2-hydroxy-4-oxo-4-(4-biphenylyl)but-2-enoic acid ethyl ester 
• 109807-20-7 ethyl 5-([1,1′-biphenyl]-4-yl)isoxazole-3-carboxylate 

Downstream Products

• 102241-79-2 5-biphenyl-4-yl-2-(4-nitro-phenyl)-2H-pyrazol-3-ylamine 
• 1314024-06-0 N-(2-(benzo[d][1,3]dioxol-5-yl)methyl)-5-(1,1'-biphenyl-4-yl)-isoxazole-3-carboxamide 
• 1314023-90-9 5-(1,1'-biphenyl-4-yl)-N-(3-phenylpropyl)isoxazole-3-carboxamide 
• 1314023-97-6 N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-5-(1,1'-biphenyl-4-yl)-isoxazole-3-carboxamide 
• 1314024-05-9 N-(benzo[d][1,3]dioxol-5-yl)-5-(1,1'-biphenyl-4-yl)isoxazole-3-carboxamide 
• 1314024-04-8 5-(1,1'-biphenyl-4-yl)-N-(2-phenylethyl)isoxazole-3-carboxamide 
• 1314024-03-7 5-(1,1'-biphenyl-4-yl)-N-(benzyl)isoxazole-3-carboxamide 
• 1431935-40-8 (5-biphenyl-4-yl)isoxazole-3-carboxylic acid isopropyl ester 

Relevant academic research and scientific papers

Synthesis and evaluation as antitubercular agents of 5-arylethenyl and 5-(hetero)aryl-3-isoxazolecarboxylate

Preclinical Research A new series of 5-aryl and 5-arylethenylisoxazole carboxylate derivatives was synthesized and evaluated for in vitro activity against Mycobacterium tuberculosis H37Rv. Several compounds exhibited minimum inhibitory concentrations in the low micromolar range (2.3-11.4 μM). A variety of substituents introduced around the isoxazole ring allowed the delineation of preliminary SARs for this new series of compounds.

New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis

Growing evidence suggests a role for the endocannabinoid (EC) system, in intestinal inflammation and compounds inhibiting anandamide degradation offer a promising therapeutic option for the treatment of inflammatory bowel diseases. In this paper, we repor